Abstract
Decades of cytotoxic and more recently immunotherapy treatments for malignant glioma have had limited success due to dynamic intra-tumoral heterogeneity. The dynamic interplay of cancer cell subpopulations has been found to be under the control of proteins in the cancer microenvironment. EGF-containing fibulin-like extracellular matrix protein (EFEMP1) (also fibulin-3) has the multiple functions of suppressing cancer growth and angiogenesis, while promoting cancer cell invasion. EFEMP1-derived tumor suppressor protein (ETSP) retains EFEMP1's anti-growth and anti-angiogenic functions while actually inhibiting cancer cell invasion. In this study, we examined the therapeutic effect on glioblastoma multiforme (GBM) of an in vitro synthesized protein, ZR30, which is based on the sequence of ETSP, excluding the signaling peptide. ZR30 showed the same effects as ETSP in blocking EGFR/NOTCH/AKT signaling pathways, when applied to cultures of multiple GBM cell lines and primary cultures. ZR30's inhibition of MMP2 activation was shown not only for GBM cells, but also for other types of cancer cells having overexpression of MMP2. A significant improvement in survival of mice with orthotopic human GBM xenografts was observed after a single...Continue Reading
References
Feb 11, 2005·International Journal of Cancer. Journal International Du Cancer·Iris TischoffAndrea Tannapfel
Apr 26, 2006·Journal of Neuro-oncology·Victor A LevinMark Baillet
Oct 19, 2006·Cancer Research·Debra A MayesYi-Hong Zhou
Apr 4, 2007·Oncogene·B DaiS Huang
Sep 11, 2008·British Journal of Cancer·L Karayan-TaponJ Roche
Oct 17, 2008·Cancer Research·Emely Castro-RiveraJohn D Minna
Feb 11, 2010·Cell Stem Cell·Nikki CharlesEric C Holland
May 27, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Vani SantoshManchanahalli R S Rao
Oct 1, 2011·Molecular Cancer·Yuanjie HuYi-Hong Zhou
Mar 10, 2012·Biomarker Insights·Abhishek ChaturbediYi-Hong Zhou
Nov 28, 2013·PloS One·Yuanjie HuYi-Hong Zhou
Jan 17, 2015·Oncoscience·Yuanjie HuYi-Hong Zhou
Jun 3, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J M SepúlvedaC Balañá
Aug 27, 2015·Oncotarget·Yuanjie HuYi-Hong Zhou
Jun 29, 2016·Oncology Reports·Hong TangSuxia Luo
Oct 8, 2016·Oncoscience·Yi-Hong ZhouMark E Linskey
Nov 9, 2017·Oncotarget·Yi-Hong ZhouCharles Limoli
Citations
Mar 6, 2019·Cancers·Riccardo Bazzoni, Angela Bentivegna
Jun 26, 2020·Cancers·Kambiz AfrasiabiYi-Hong Zhou
Feb 29, 2020·OncoTargets and Therapy·Liang SongXiao-Peng He
Oct 18, 2018·Investigational New Drugs·Peng-Jin MeiYue-Chao Fan
Jan 11, 2020·Cancer Science·Chao KeYi-Hong Zhou